quinoxalines has been researched along with Cystadenocarcinoma, Serous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corona, P; Costi, MP; Frassineti, C; Guerrieri, D; Ligabue, A; Luciani, R; Marverti, G; Moruzzi, MS; Paglietti, G; Piras, S; Vitale, G | 1 |
| Costi, MP; Farina, D; Frassineti, C; Guerrieri, D; Ligabue, A; Marverti, G; Monti, MG; Moruzzi, MS; Paglietti, G; Piras, S | 1 |
2 other study(ies) available for quinoxalines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Fluorouracil; Folic Acid Antagonists; Humans; Ovarian Neoplasms; Quinoxalines; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2009 |
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Drug Synergism; Female; Folic Acid Antagonists; Humans; Ovarian Neoplasms; Quinoxalines; Reactive Oxygen Species; Spermine | 2010 |